Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10080733 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(10 years from now) | |
US8669281 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(10 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9090558 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(10 years from now) |
Market Authorisation Date: 29 October, 2019
Treatment: Method of treating multiple sclerosis
Dosage: CAPSULE, DELAYED RELEASE;ORAL
18
United States
4
Singapore
4
New Zealand
3
Australia
3
Canada
2
Israel
2
Lithuania
2
Hungary
2
Korea, Republic of
2
China
2
Japan
2
EA
2
European Union
1
Denmark
1
Mexico
1
Hong Kong
1
Slovenia
1
Brazil
1
Croatia
1
Portugal
1
Cyprus
1
Spain
1
Poland
1
RS
1
Ukraine
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic